Company profile
Affini-T Therapeutics, Inc.
Privately held: no public share price (Privately held T-cell therapy biotech; no IPO, shares traded only on private secondary markets. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.crunchbase.com/organization/affini-t-therapeutics])
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | KRAS G12VSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.